| SUnSET, a nonradioactive method to monitor protein synthesis EK Schmidt, G Clavarino, M Ceppi, P Pierre Nature methods 6 (4), 275-277, 2009 | 1629 | 2009 |
| MicroRNA-155 modulates the interleukin-1 signaling pathway in activated human monocyte-derived dendritic cells M Ceppi, PM Pereira, I Dunand-Sauthier, E Barras, W Reith, MA Santos, ... Proceedings of the national academy of sciences 106 (8), 2735-2740, 2009 | 916 | 2009 |
| MHC class II stabilization at the surface of human dendritic cells is the result of maturation-dependent MARCH I down-regulation A De Gassart, V Camosseto, J Thibodeau, M Ceppi, N Catalan, P Pierre, ... Proceedings of the National Academy of Sciences 105 (9), 3491-3496, 2008 | 305 | 2008 |
| Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy C Claus, C Ferrara, W Xu, J Sam, S Lang, F Uhlenbrock, R Albrecht, ... Science translational medicine 11 (496), eaav5989, 2019 | 243 | 2019 |
| Multiple recent horizontal transfers of a large genomic region in cheese making fungi K Cheeseman, J Ropars, P Renault, J Dupont, J Gouzy, A Branca, ... Nature communications 5 (1), 2876, 2014 | 211 | 2014 |
| Interaction of classical swine fever virus with dendritic cells CP Carrasco, RC Rigden, IE Vincent, C Balmelli, M Ceppi, O Bauhofer, ... Journal of general virology 85 (6), 1633-1641, 2004 | 128 | 2004 |
| Selective enhancement of gene transfer by steroid-mediated gene delivery A Rebuffat, A Bernasconi, M Ceppi, H Wehrli, SB Verca, M Ibrahim, ... Nature biotechnology 19 (12), 1155-1161, 2001 | 111 | 2001 |
| Regulation of translation is required for dendritic cell function and survival during activation H Lelouard, EK Schmidt, V Camosseto, G Clavarino, M Ceppi, HT Hsu, ... The Journal of cell biology 179 (7), 1427-1439, 2007 | 98 | 2007 |
| Protein phosphatase 1 subunit Ppp1r15a/GADD34 regulates cytokine production in polyinosinic: polycytidylic acid-stimulated dendritic cells G Clavarino, N Cláudio, A Dalet, S Terawaki, T Couderc, L Chasson, ... Proceedings of the National Academy of Sciences 109 (8), 3006-3011, 2012 | 83 | 2012 |
| Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive … A Schneeweiss, TW Park-Simon, J Albanell, U Lassen, J Cortés, V Dieras, ... Investigational new drugs 36, 848-859, 2018 | 76 | 2018 |
| First-in-human phase I study of lumretuzumab, a glycoengineered humanized anti-HER3 monoclonal antibody, in patients with metastatic or advanced HER3-positive solid tumors D Meulendijks, W Jacob, M Martinez-Garcia, A Taus, MP Lolkema, ... Clinical Cancer Research 22 (4), 877-885, 2016 | 73 | 2016 |
| Identification of classical swine fever virus protein E2 as a target for cytotoxic T cells by using mRNA-transfected antigen-presenting cells M Ceppi, MGM de Bruin, T Seuberlich, C Balmelli, S Pascolo, N Ruggli, ... Journal of general virology 86 (9), 2525-2534, 2005 | 64 | 2005 |
| Ribosomal protein mRNAs are translationally-regulated during human dendritic cells activation by LPS M Ceppi, G Clavarino, E Gatti, EK Schmidt, A de Gassart, D Blankenship, ... Immunome research 5, 1-12, 2009 | 57 | 2009 |
| Double‐stranded secondary structures on mRNA induce type I interferon (IFN α/β) production and maturation of mRNA‐transfected monocyte‐derived dendritic cells M Ceppi, N Ruggli, V Tache, H Gerber, KC McCullough, A Summerfield The Journal of Gene Medicine: A cross‐disciplinary journal for research on …, 2005 | 51 | 2005 |
| Direct estrogen receptor (ER)/HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer D Collins, W Jacob, JM Cejalvo, M Ceppi, I James, M Hasmann, J Crown, ... PLoS One 12 (5), e0177331, 2017 | 44 | 2017 |
| Phase Ib study of lumretuzumab plus cetuximab or erlotinib in solid tumor patients and evaluation of HER3 and heregulin as potential biomarkers of clinical activity D Meulendijks, W Jacob, EE Voest, M Mau-Sorensen, M Martinez-Garcia, ... Clinical Cancer Research 23 (18), 5406-5415, 2017 | 38 | 2017 |
| A first-in-human study of the fibroblast activation protein–targeted, 4-1BB agonist RO7122290 in patients with advanced solid tumors I Melero, T Tanos, M Bustamante, MF Sanmamed, E Calvo, I Moreno, ... Science translational medicine 15 (695), eabp9229, 2023 | 30 | 2023 |
| A diagnostic genetic test for the physical mapping of germline rearrangements in the susceptibility breast cancer genes BRCA1 and BRCA2 K Cheeseman, E Rouleau, A Vannier, A Thomas, A Briaux, C Lefol, ... Human mutation 33 (6), 998-1009, 2012 | 30 | 2012 |
| EGFR and HER3 signaling blockade in invasive mucinous lung adenocarcinoma harboring an NRG1 fusion HS Kim, JY Han, DH Shin, KY Lim, GK Lee, JY Kim, W Jacob, M Ceppi, ... Lung Cancer 124, 71-75, 2018 | 29 | 2018 |
| Abstract LB-085: RG70099: A novel, highly potent dual IDO1/TDO inhibitor to reverse metabolic suppression of immune cells in the tumor micro-environment G Gyulveszi, C Fischer, M Mirolo, M Stern, L Green, M Ceppi, H Wang, ... Cancer Research 76 (14_Supplement), LB-085-LB-085, 2016 | 23 | 2016 |
Philippe PierreGroup Leader, Research Director, CNRS, Centre d'Immunologie de Marseille Luminy在 ciml.univ-mrs.fr 的电子邮件经过验证